NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort

Document Details

Document Type
Pub Defense Publication
Publication Date
Jul 01, 2018
Source ID
10.1016/j.rmed.2018.06.005

Entities

People

  • Carlos H. Martinez
  • Christopher B. Cooper
  • David J. Couper
  • Eric A. Hoffman
  • Eugene R. Bleecker
  • Fernando J. Martinez
  • J. Michael Wells
  • Jeffrey L. Curtis
  • Jerry A. Krishnan
  • Mark T Dransfield
  • Meilan K. Han
  • Meng Xia
  • Nadia N. Hansel
  • Prescott G. Woodruff
  • R. Graham Barr
  • Richard E. Kanner
  • Robert Paine Iii
  • Russell P. Bowler
  • Stephen P. Peters
  • Surya P. Bhatt
  • Susan Murray
  • Victor E. Ortega
  • Wassim W Labaki

Organizations

  • Alpha-1 Foundation
  • Amgen
  • AstraZeneca
  • AstraZeneca (United States)
  • Boehringer Ingelheim
  • Chiron Corporation
  • Cystic Fibrosis Foundation
  • GSK
  • Gilead Sciences
  • IQVIA Holdings, Inc.
  • National Heart, Lung, and Blood Institute
  • National Institutes of Health
  • Pfizer
  • Teva- Pharmaceutical Industries Ltd.
  • United States Department of Defense
  • United States Department of Veterans Affairs